Abstract
Abuse-deterrent opioid formulations are receiving renewed interest in light of the increasing legitimate medical use of prescription opioids for the adequate treatment of pain. Unfortunately, there is an inevitable associated potential for misuse, diversion, and abuse. The challenges of deterrence are significant: opioid abusers are a heterogeneous population; studies on drug “liking” and opioid “attractiveness” are informative, but mainly rely on reports from users who are not reliable respondents; drug “liking” scores are useful, but it is unclear how much drug “liking” must be reduced in order to achieve an actual reduction in abuse levels; and the most popular drugs among opioid abusers appear to be those that meet a complex combination of both positive and negative criteria including things like availability, pricing, and how easily the drug’s illicit use can be concealed. Several abuse-deterrent formulations have been introduced or are in development. Epidemiological studies will have to be conducted to evaluate their effectiveness. Although there are currently more questions than answers, such products are clearly of medical and societal importance.
Keywords: Opioids, opioid abuse, opioid misuse, abuse-deterrent opioids, abuse-resistant opioids, pain, availability, pricing, drug, effectiveness.
Current Pharmaceutical Design
Title:Non-Analgesic Effects of Opioids: Factors Relevant to Opioid Abuse and Abuse- Deterrent Formulations
Volume: 18 Issue: 37
Author(s): Joseph V. Pergolizzi, Robert B. Raffa, Jason S. Pergolizzi and Robert Taylor
Affiliation:
Keywords: Opioids, opioid abuse, opioid misuse, abuse-deterrent opioids, abuse-resistant opioids, pain, availability, pricing, drug, effectiveness.
Abstract: Abuse-deterrent opioid formulations are receiving renewed interest in light of the increasing legitimate medical use of prescription opioids for the adequate treatment of pain. Unfortunately, there is an inevitable associated potential for misuse, diversion, and abuse. The challenges of deterrence are significant: opioid abusers are a heterogeneous population; studies on drug “liking” and opioid “attractiveness” are informative, but mainly rely on reports from users who are not reliable respondents; drug “liking” scores are useful, but it is unclear how much drug “liking” must be reduced in order to achieve an actual reduction in abuse levels; and the most popular drugs among opioid abusers appear to be those that meet a complex combination of both positive and negative criteria including things like availability, pricing, and how easily the drug’s illicit use can be concealed. Several abuse-deterrent formulations have been introduced or are in development. Epidemiological studies will have to be conducted to evaluate their effectiveness. Although there are currently more questions than answers, such products are clearly of medical and societal importance.
Export Options
About this article
Cite this article as:
V. Pergolizzi Joseph, B. Raffa Robert, S. Pergolizzi Jason and Taylor Robert, Non-Analgesic Effects of Opioids: Factors Relevant to Opioid Abuse and Abuse- Deterrent Formulations, Current Pharmaceutical Design 2012; 18 (37) . https://dx.doi.org/10.2174/138161212803582379
DOI https://dx.doi.org/10.2174/138161212803582379 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Does A Subclinical Cardiotoxic Effect of Clozapine Exist? Results from a Follow-up Pilot Study
Cardiovascular & Hematological Agents in Medicinal Chemistry Abelson Tyrosine-Protein Kinase 1 as Principal Target for Drug Discovery Against Leukemias. Role of the Current Computer-Aided Drug Design Methodologies
Current Topics in Medicinal Chemistry Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Three Dimensional Molecular Field Analysis of Thiomorpholine Analogs of TACE Inhibitors Using Receptor Based Alignment
Letters in Drug Design & Discovery Meta-analysis Identifies Tumor Necrosis Factor-alpha and Interleukin-1 beta as Diagnostic Biomarkers for Bacterial and Aseptic Meningitis
Current Neurovascular Research ERRATUM 2
Current Neuropharmacology UDP-Glucuronosyltransferases
Current Drug Metabolism Quality of Education and Memory Test Performance in Older Men: The New York University Paragraph Recall Test Normative Data
Current Alzheimer Research Abnormal Clock Gene Expression and Locomotor Activity Rhythms in Two Month-Old Female APPSwe/PS1dE9 Mice
Current Alzheimer Research Recent Developments in Anxiety Disorders
Recent Patents on CNS Drug Discovery (Discontinued) MicroRNA-451 Aggravates Kainic Acid-induced Seizure and Neuronal Apoptosis by Targeting GDNF
Current Neurovascular Research Role of Cation-Chloride-Cotransporters (CCC) in Pain and Hyperalgesia
Current Topics in Medicinal Chemistry Cholesterol Oxidation Products and Disease: An Emerging Topic of Interest in Medicinal Chemistry
Current Medicinal Chemistry Anti-Angiogenic Effects of Resveratrol on Cerebral Angiogenesis
Current Neurovascular Research An Overview on Application of Natural Substances Incorporated with Electrospun Nanofibrous Scaffolds to Development of Innovative Wound Dressings
Mini-Reviews in Medicinal Chemistry Targeting the Brain: Advances in Drug Delivery
Current Pharmaceutical Biotechnology Expanding Spectrum of Sodium Potassium Chloride Co-transporters in the Pathophysiology of Diseases
Current Neuropharmacology Peripheral Benzodiazepine Receptor Ligands and their Anti-Inflammatory Effects
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Recent Advances in Nutrition for the Treatment of Depressive Disorder
Current Pharmaceutical Design Opioids in the Frame of New Psychoactive Substances Network: A Complex Pharmacological and Toxicological Issue
Current Molecular Pharmacology